Viking Therapeutics, Inc. (VKTX) Deep Dive Video

Summary

Viking is spending aggressively to turn VK2735 into the first credible dual-formulation (injectable + oral) challenger to the Novo/Lilly obesity duopoly—while keeping a high-upside MASH asset in reserve for partnering.

View VKTX stock page · Read the VKTX research report

Loading the video player…